Latest News

TDC launches new website!

November 24, 2017 /in Latest News

TDC is pleased to announce the launch of a new website! We have added enhanced content tailored to provide the most useful resource possible to both our internal UHN community, as well as the external industry and investor communities. For instance, we've now provided an up-to-date searchable listing of all of UHN's currently availble technologies, information on working successfully with TDC and UHN, frequently asked questions, and  access to various document templates even when off the UHN network, in addition to other useful content. 

We will be releasing additional helpful resources on commercialization at UHN in the coming months as well.  We welcome you to peruse our new website for this and other new and...

Read More

Video recording now available: TDC's Panel on Diagnostics & Prognostics: Journey to Patient Impact

November 24, 2017 /in Latest News

On November 21st, UHN's Technology Development & Commercialization invited the UHN Community to join anexciting panel of experts in the diagnostics/prognostics area as they discussed the challenges to and strategies for getting these tests into the market.  We were privileged to have panelsts from LifeLabsDynacareGeneseeq Technology, and Bereskin & Parr present to discuss the pathway to developing diagnostics/prognostics towards patient impact.  The session was recorded for those that were unable to attend and can be viewed in its entirety here

UHN Named Canada’s Top Research Hospital

November 09, 2017 /in Latest News

UHN named the top-funded research hospital in Canada by RE$EARCH Infosource Inc.

Announced on Nov 9, 2017

UHN was ranked number one on the 2017 list of Canada’s Top 40 Research Hospitals, released by RE$EARCH Infosource Inc.

The annual rankings compare research hospitals across Canada according to their research funding data. Funds that were considered included grants, contributions and contracts from all internal and external government and non-government sources.

UHN research expenditures totaled $332 million in the 2016 fiscal year, a value that earned the UHN the top rank for the seventh year in a row. In comparison to last year, UHN research expenditure funding increased by...

Read More

UHN Start-up Thornhill Medical Wins Second Place in International Marine Innovation and Entrepreneurship Competition in China

November 07, 2017 /in Latest News

BEIJING, Qingdao, November 6, 2017 

International Marine Innovation and Entrepreneurship Competition (MTEC) Finals held in Qingdao Blue Valley on the 6th. After the selection of 10 preliminary matches in 6 countries, a total of 50 teams entered the finals. Eventually, the Eco-Friendly Marine Coatings team from Germany won the championship and received 500,000 RMB bonuses and the start-up counseling and support services provided by Shandong University.  The team from Thornhill Medical (an innovative medical device company) from Toronto Canada was the runner up in second place and recieved 300,000 RMB bonuses and start-up counseling and support services as well. 

2017 International Marine Innovation and Entrepreneurship Competition (MTEC) is by far one of the largest marine international innovation and entrepreneurship competitions in the world. It is co-founded and...

Read More

The Jenex Corporation, in Collaboration with UHN’s Techna Institute, Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

October 16, 2017 /in Latest News

Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap.

Dr. Alyson Kelvin at UHN reported the following:

"To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells...

Read More

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis

October 10, 2017 /in Latest News
Cystinosis Program Becomes Company’s Fourth Gene Therapy  for Lysosomal Storage Disorders

Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to cystinosis. This program becomes AVROBIO’s fourth gene therapy for lysosomal storage disorders (LSDs), and with an anticipated IND filing later this year is expected to enter the clinic in early 2018. The cystinosis program was licensed from GenStem Therapeutics, Inc. Terms of the license agreement were not disclosed.

“This cystinosis program is a strong strategic fit with our pipeline,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “We are pleased to...

Read More

Bauer Launches Innovative NeuroShield in Canada, Co-Invented by the Founder of UHN Spin-off Thornhill Medical

September 26, 2017 /in Latest News

PRESS RELEASE  UPDATED: SEP 26, 2017 08:00 EDT

NeuroShield

TORONTO, September 26, 2017 (Newswire.com)  Bauer, the world's leading manufacturer of ice hockey equipment, recently launched the first athletic product clinically shown to help protect the brain from the inside during sports-related impacts. Continuing Bauer Hockey's rich history of delivering game-changing technologies, the BAUER NeuroShield collar revolutionizes head protection with an innovative approach that delivers peer-reviewed scientific benefits.

The technology behind NeuroShield was discovered by Dr. David Smith, who was inspired by the woodpecker's ability to...

Read More

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

September 21, 2017 /in Latest News

Pre-Clinical Program Becomes Company’s Third GeneTherapy
for Lysosomal Storage Disorders

Pre-Clinical Proof-of-Concept Demonstrated

Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program and pre-Phase 1/2 Gaucher program. AVROBIO’s gene therapy for Pompe disease utilizes a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes.

“Pompe disease is a serious lysosomal storage disorder with significant unmet need; our gene therapy is...

Read More

UHN Start-up MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

September 18, 2017 /in Latest News

MISSISSAUGA, ON, Sept. 8, 2017 /CNW/ - MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury.

"This is a major milestone in the evolution of our company," said MyndTec Founder Dr. Milos R. Popovic.  "We are delighted that we can now offer this life-changing therapy to patients in the U.S. with upper extremity paralysis."

MyndTec intends to initiate a pilot launch of MyndMove® into the U.S. market which complements a product introduction already underway in Canada with a previously announced approval from Health Canada.

MyndMove® Therapy is a functional electric stimulation (FES) based...

Read More

UHN’s Techna Institute, in Collaboration with Jenex, to release initial results on Zika virus deactivation testing

September 14, 2017 /in Latest News

 

For Immediate Release

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES

Jenex Reports Expected Date of Test Results for TherOZap™ at Inactivating the Zika Virus

Toronto, Ontario – (September 14, 2017) The Jenex Corporation (“Jenex”, or the “Company”, NEX: JEN.H), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October.  Techna Institute has informed Jenex that additional time may be required outside of the first week of October if necessary to provide the data.  Jenex expects to report additional...

Read More

We’re hiring: Commercialization Intern (8 months full-time, Oct-May)

September 13, 2017 /in Latest News

 

Are you a graduated student with an interest in commercialization? Experience with market analysis? A scientific background? Join the TDC team as our TDC Commercialization Intern starting this Fall, 2017.

Please note this opportunity is not available to current students.

Job Title:  Commercialization Intern (8 months full-time, Oct-May)
Company Name:  University Health Network, Office of Technology Development & Commercialization
Website: http://tdc.uhnresearch.ca/
Location:   MaRS Discovery District, 101...
Read More

Tribute to Dr. Michael Sharpe, UHN Researcher, for Contribution to the Advancement of Radiation Therapy

August 31, 2017 /in Latest News

TDC is proud to have helped enable an important advance in radiation therapy and radiation therapy training, and to honor the memory of one of our great inventors, Dr. Michael Sharpe.

In this video, UHN outlines the impact of the automatic treatment planning innovations it recently licensed to RaySearch, enabling algorithms from Princess Margaret Cancer Center to be integrated into RayStation.

UHN Start-up VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer

August 21, 2017/in  

SOUTH SAN FRANCISCO, CA — (Marketwired) — 08/08/17 – VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/359,517 regarding proprietary methods for producing hematopoietic precursor stem cells, which are stem cells that give rise to all of the blood cells and most of the bone marrow cells in the body, with potential to impact both direct and supportive therapy for autoimmune disorders and cancer.

The breakthrough technology covered by the...

Read More

BlueRock Therapeutics, Start-up based on UHN Technology, Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership

August 17, 2017/in  

Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicinebluerock

Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations

TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announces the expansion of the company’...

Read More

We’re hiring: Licensing and Commercialization Associate

August 8, 2017/in   

Join the TDC Team at UHN!  

Please apply online.

Job Posting #809308
Position: Licensing and Commercialization Associate
Site: MaRS – Heritage Building
Department: Technology Development & Commercialization (TDC) 
Reports to: Team Lead, Licensing and Commercialization
Salary Range: Commensurate with experience and consistent with UHN Compensation Policy
Status: Temporary Full-Time, 1 year contract

University Health Network (UHN) is Canada’s largest research hospital and has a proud history of innovative research and important discoveries. Researchers at UHN are focused on...

Read More

UHN Start-up Acumyn dramatically reduces the time spent on quality assurance

July 28, 2017/in  

acumyn 2

Source: Canadian Healthcare Technology, VOL.22, NO.5 JUNE/JULY 2017

Dr. Christopher Paige named UHN Inventor of the Year

June 15, 2017/in   

Longtime UHN researcher Dr. Christopher Paige has been named Inventor of the Year for his work in immune-oncology, a promising therapeutic approach based on the premise that a patient's own immune system has powerful cancer-fighting capabilities if correctly activated and targeted.

Dr. Paige, who for close to two decades as UHN's Vice-President of Research, and later as Executive Vice- President (EVP) of Science and Research, championed commercialization as a strategy to transform discoveries into practical medical products to benefit patients, received the award at yesterday's UHN Annual General Meeting in the MaRS Auditorium.

Each year,...

Read More

Princess Margaret Cancer Centre Innovation Acceleration Fund Announces 1st Round of 2017 Awards to Researchers to Develop Early Stage Technologies

June 15, 2017/in   

June 2nd, 2017 TORONTO, ON – The Princess Margaret Cancer Centre’s Innovation Accelerator Fund (IAF) Leadership Board has announced three new awardees in its first funding round of 2017.  The IAF was established by The Princess Margaret Cancer Foundation in collaboration with University Health Network’s Technology Development and Commercialization Office in January 2016 to help investigators at the Princess Margaret Cancer Centre accelerate their early-stage research discoveries towards commercialization.  The fund provides a maximum of $250,000 per proposal, helping to take novel technologies from bench-to-bedside. The three winning projects of the latest call include:

Generation of inhibitors targeting V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS...

Read More

UHN Spin-Off Thornhill Medical’s MOVES® SLC™ Portable Emergency Life Support System Receives 510K Clearance From The US FDA

June 8, 2017/in  

TORONTO, June 8, 2017 /PRNewswire/ – Thornhill Medical, has received notification from the US FDA that the MOVES® SLC™ Portable Emergency Life Support System has received 510K clearance. This approval expands the capabilities of the current MOVES® SLC™ system, including Pediatric Settings, Expanded Patient Monitoring Modes, New Ventilator Modes, and a Remote Monitoring and Control Interface.

“The US FDA 510K clearance represents a significant milestone in the development of our emergency medical device portfolio. The MOVES® SLC™ has been tested in extreme conditions of temperature, altitude, shock, vibration, EMC, sand, dust, and rain. It has also been fully evaluated by the US Army Aeromedical Research Laboratory at Ft. Rucker (USAARL). As such, the MOVES® SLC™ is the ideal solution for...

Read More

The Ministry of Health and Long Term Care of Ontario launches a home sleep test demonstration project with BresoDx®

May 25, 2017/in  

News Release

The Ministry of Health and Long Term Care of Ontario launches a home sleep test demonstration project with BresoDx®,  

Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec and a technology developed at Toronto Rehabilitation Institute of the University Health Network (UHN), has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province, patients and sleep physicians will have the option to diagnose sleep apnea in the home.

bresotec